EGFR and adenocarcinoma: In patients with advanced NSCLC, EGFR mutations, ALK gene fusion, RET gene fusion, younger age (≤60 years), lymph node N2‐N3 metastasis and the pathological type of adenocarcinoma are all independent risk factors for brain metastasis.